8-methylquinoxaline-2-one | 61148-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-methylquinoxaline-2-one
• 英文别名: 8-methyl-1H-quinoxalin-2-one；8-methylquinoxaline-2(1H)-one；8-Methylquinoxalin-2-ol；8-methyl-1H-quinoxalin-2-one
• CAS: 61148-22-9
• 化学式: C₉H₈N₂O
• 分子量: 160.175
• InChiKey: NZKPWVAKHWJDAX-UHFFFAOYSA-N

物化性质

• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  8-methylquinoxaline-2-one 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 三氯氧磷 作用下， 以 四氯化碳 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 8-(dibromomethyl)-2-methoxyquinoxaline
  参考文献：
  名称：

  Design, Synthesis, and Characterization of Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram-Positive Activity

  摘要：

  There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K channel block. On the other hand, analog 49e displayed lower hERG K channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.

  DOI：

  10.1021/jm400963y
• 作为产物：
  描述：

  AR-甲基-AR-硝基苯胺 在 吡啶 、 sodium dithionite 、 五氯化磷 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 苯 为溶剂， 反应 12.0h， 生成 8-methylquinoxaline-2-one
  参考文献：
  名称：

  Design, Synthesis, and Characterization of Novel Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Potent Anti-Gram-Positive Activity

  摘要：

  There is an urgent need for new antibacterial drugs that are effective against infections caused by multidrug-resistant pathogens. Novel nonfluoroquinolone inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) have the potential to become such drugs because they display potent antibacterial activity and exhibit no target-mediated cross-resistance with fluoroquinolones. Bacterial topoisomerase inhibitors that are built on a tetrahydropyran ring linked to a bicyclic aromatic moiety through a syn-diol linker show potent anti-Gram-positive activity, covering isolates with clinically relevant resistance phenotypes. For instance, analog 49c was found to be a dual DNA gyrase topoisomerase IV inhibitor, with broad antibacterial activity and low propensity for spontaneous resistance development, but suffered from high hERG K channel block. On the other hand, analog 49e displayed lower hERG K channel block while retaining potent in vitro antibacterial activity and acceptable frequency for resistance development. Furthermore, analog 49e showed moderate clearance in rat and promising in vivo efficacy against Staphylococcus aureus in a murine infection model.

  DOI：

  10.1021/jm400963y

文献信息

• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Cianchetta Giovanni

  公开号：US20140288081A1

  公开（公告）日：2014-09-25

  Compounds of general formula I: and compositions comprising compounds of general formula I that modulate pyruvate kinase are described herein. Also described herein are methods of using the compounds that modulate pyruvate kinase in the treatment of diseases.

  通式I的化合物： 以及包含调节丙酮酸激酶的通式I化合物的组合物在此处被描述。此外，在此处还描述了利用调节丙酮酸激酶的化合物治疗疾病的方法。
• [EN] PRMT5 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE PRMT5 ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100734A1

  公开（公告）日：2014-06-26

  Described herein are compounds of formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组成物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• [EN] NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY<br/>[FR] NOUVEAUX COMPOSES PRESENTANT UNE ACTIVITE ANTIBACTERIENNE
  申请人：CHEMIE MORPHOCHEM AG FUER KOMB

  公开号：WO2006021448A1

  公开（公告）日：2006-03-02

  The present invention describes novel anti-bacterial compounds of formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase.

  本发明描述了具有通式(I)的新型抗菌化合物。这些化合物在其他方面，尤其是作为DNA促旋酶抑制剂，具有研究价值。
• CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES
  申请人：Hubschwerlen Christian

  公开号：US20090105232A1

  公开（公告）日：2009-04-23

  The invention relates to antibiotic cyclohexyl or piperidinyl carboximide derivatives of formula (I) wherein R 1 represents hydrogen, halogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, cyano or COOR 2 , R 2 being (C 1 -C 4 )alkyl; one or two of U, V, W and X represent(s) N and the remaining represent each CH, or, in the case of X, may also represent CR X , R X being a halogen atom; either B represents N and A represents CH 2 CH 2 or CH(OR 3 )CH 2 , or B represents CH or C(OR 4 ) and A represents OCH 2 , CH 2 CH(OR 5 ), CH(OR 6 )CH 2 , CH(OR 7 )CH(OR 8 ), CH═CH or CH 2 CH 2 ; each of R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 represents independently hydrogen, SO 3 H, PO 3 H 2 , CH 2 OPO 3 H 2 or COR 9 , R 9 being either CH 2 CH 2 COOH or such that R 9 —COOH is naturally occurring amino acid or dimethylaminoglycine; and to salts of such compounds of formula (I).

  该发明涉及公式（I）的抗生素环己基或哌啶基羧酰胺衍生物，其中R1代表氢、卤素、（C1-C4）烷基、（C1-C4）烷氧基、氰基或COOR2，R2为（C1-C4）烷基；U、V、W和X中的一个或两个代表N，其余代表CH，或者在X的情况下，也可以表示为CRX，RX为卤素原子；B表示N，A表示CH2CH2或CH(OR3)CH2，或者B表示CH或C(OR4)，A表示OCH2，CH2CH(OR5)，CH(OR6)CH2，CH(OR7)CH(OR8)，CH═CH或CH2CH2；R3、R4、R5、R6、R7和R8中的每一个独立地代表氢、SO3H、PO3H2、CH2OPO3H2或COR9，R9为CH2CH2COOH或R9-COOH为天然存在的氨基酸或二甲基氨基甘氨酸；以及公式（I）中此类化合物的盐。